| Paroxysmal nocturnal hemoglobinuria
Bkemv vs PiaSky
Side-by-side clinical, coverage, and cost comparison for paroxysmal nocturnal hemoglobinuria.Deep comparison between: Bkemv vs Piasky with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPiasky has a higher rate of injection site reactions vs Bkemv based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Piasky but not Bkemv, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Bkemv
Piasky
At A Glance
IV infusion
Every 2 weeks
Complement C5 inhibitor
IV infusion / SC injection
Every 4 weeks (maintenance)
Complement C5 inhibitor
Indications
- Paroxysmal nocturnal hemoglobinuria
- Atypical Hemolytic Uremic Syndrome
- Myasthenia Gravis, Generalized
- Paroxysmal nocturnal hemoglobinuria
Dosing
Paroxysmal nocturnal hemoglobinuria 600 mg IV weekly for 4 weeks, then 900 mg at week 5, then 900 mg every 2 weeks thereafter.
Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized 900 mg IV weekly for 4 weeks, then 1,200 mg at week 5, then 1,200 mg every 2 weeks thereafter.
Atypical Hemolytic Uremic Syndrome (pediatric, <18 years) Weight-based IV dosing: induction 300-900 mg and maintenance 300-1,200 mg every 2-3 weeks depending on body weight (5 kg and over).
Paroxysmal nocturnal hemoglobinuria Loading: 1,000 mg (>=40 kg to <100 kg) or 1,500 mg (>=100 kg) IV on Day 1, then 340 mg SUBQ on Days 2, 8, 15, and 22; maintenance 680 mg (>=40 kg to <100 kg) or 1,020 mg (>=100 kg) SUBQ every 4 weeks starting Day 29.
Contraindications
- Unresolved serious Neisseria meningitidis infection
- Unresolved serious Neisseria meningitidis infection
- Known serious hypersensitivity reaction to crovalimab or any excipient
Adverse Reactions
Most common (>=5%) Headache, nasopharyngitis, back pain, nausea, fatigue, cough, herpes simplex infections, musculoskeletal pain, hypertension, diarrhea, vomiting, pyrexia, peripheral edema.
Serious Meningococcal infections, other serious infections, thrombosis, infusion-related reactions, disease manifestation exacerbation after discontinuation.
Postmarketing Fatal or serious infections (Neisseria gonorrhoeae, Neisseria meningitidis, Neisseria species), cholestatic or mixed pattern liver injury with elevated liver enzymes and bilirubin.
Most common (>=10%) Infusion-related reaction, respiratory tract infection, viral infection, Type III hypersensitivity reaction, peripheral edema, headache
Serious Epistaxis, pneumonia, infusion-related reaction, pyelonephritis, COVID-19, hypovolemic shock, nasopharyngitis, urinary tract infection
Pharmacology
Complement C5 inhibitor; eculizumab-aeeb is a recombinant humanized monoclonal IgG2/4kappa antibody that specifically binds complement protein C5 with high affinity, inhibiting its cleavage to C5a and C5b and preventing generation of the terminal complement complex C5b-9, thereby inhibiting terminal complement-mediated intravascular hemolysis in PNH and complement-mediated thrombotic microangiopathy in aHUS.
Crovalimab-akkz is a humanized IgG1 monoclonal antibody that binds with high affinity to complement protein C5, inhibiting its cleavage into C5a and C5b and preventing formation of the membrane attack complex (MAC), thereby inhibiting terminal complement-mediated intravascular hemolysis in patients with PNH.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Bkemv
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
Piasky
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Bkemv
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Piasky
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Bkemv
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Piasky
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Bkemv.
Cost estimate not availableAssistance Fund: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.